Robert John Mentz, MD, FACC

General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Thoratec(MODEST), Luitpold Pharmaceuticals, Inc(MODEST), Janssen(MODEST), HeartWare(MODEST), Abbott Laboratories(MODEST), Novartis Corporation(SIGNIFICANT), Akros(MODEST), Bayer Healthcare Pharmaceuticals(SIGNIFICANT), Boehringer Ingelheim Pharmaceuticals, Inc(SIGNIFICANT), Merck & Co., Inc.(SIGNIFICANT), Sanofi-Aventis(SIGNIFICANT), Amgen Inc.(SIGNIFICANT), AstraZeneca Pharmaceuticals(MODEST), Medtronic(MODEST), Boston Scientific(MODEST), Eli Lilly and Company(SIGNIFICANT), Roche(MODEST) RESEARCH/RESEARCH GRANTS: Amgen(NONE), AstraZeneca Pharmaceuticals(NONE), Bristol-Myers Squibb Company (NONE), Gilead Sciences(NONE), Otsuka Pharmaceutical Co.(NONE), ResMed(NONE), Novartis Corporation(NONE), GlaxoSmithKline(NONE), Medtronic(NONE), Bayer Healthcare Pharmaceuticals(NONE), Merck & Co., Inc.(NONE), Luitpold Pharmaceuticals, Inc(NONE), American Regent(NONE), Vifor(MODEST), Cytokinetics(SIGNIFICANT), Fast Biomedical(SIGNIFICANT), Sanofi-Aventis(MODEST), Respicardia(MODEST) OTHER FINANCIAL BENEFIT: Gilead Sciences, Inc. (MODEST), Vifor(SIGNIFICANT)

View Full Disclosure